FABIAN SANCHIS GOMAR-rekin lankidetzan egindako argitalpenak (14)

2021

  1. Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis

    Progress in Cardiovascular Diseases, Vol. 68, pp. 70-77

2020

  1. Non-coding RNAs and Coronary Artery Disease

    Advances in experimental medicine and biology, Vol. 1229, pp. 273-285

  2. Oxidative stress and inflammation in covid-19-associated sepsis: The potential role of anti-oxidant therapy in avoiding disease progression

    Antioxidants, Vol. 9, Núm. 10, pp. 1-20

2017

  1. Challenges in the analysis of epigenetic biomarkers in clinical samples

    Clinical Chemistry and Laboratory Medicine, Vol. 55, Núm. 10, pp. 1474-1477

2016

  1. Epigenetic Mechanisms as Key Regulators in Disease: Clinical Implications

    Epigenetic Biomarkers and Diagnostics (Elsevier Inc.), pp. 37-66

  2. Epigenetic mechanisms as key regulators in disease: Clinical implications

    Epigenetic biomarkers and diagnostics (Amsterdam [etc.]: Elsevier, 2016), pp. 38-67

2014

  1. Erythropoietin and the heart: Physiological effects and the therapeutic perspective

    International Journal of Cardiology, Vol. 171, Núm. 2, pp. 116-125

  2. Mitochondrial biogenesis in health and disease. Molecular and therapeutic approaches

    Current Pharmaceutical Design, Vol. 20, Núm. 35, pp. 5619-5633

  3. Physical exercise and epigenetic modulation: Elucidating intricate mechanisms

    Sports Medicine, Vol. 44, Núm. 4, pp. 429-436

2012

  1. Epigenetic biomarkers: A new perspective in laboratory diagnostics

    Clinica Chimica Acta, Vol. 413, Núm. 19-20, pp. 1576-1582

  2. Irisin: A new potential hormonal target for the treatment of obesity and type 2 diabetes

    Journal of Diabetes

  3. Physical exercise as an epigenetic modulator: Eustress, the "positive stress" as an effector of gene expression

    Journal of Strength and Conditioning Research, Vol. 26, Núm. 12, pp. 3469-3472

2011

  1. Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?

    Movement Disorders, Vol. 26, Núm. 5, pp. 769-771

2010

  1. Desmopresssin and hemodilution: Implications in doping

    International Journal of Sports Medicine, Vol. 31, Núm. 1, pp. 5-9